ReviewNature cancer2025
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.
Review in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Carrier-free nanomodulators reprogramming acetate metabolism for cancer photo-immunotherapy via c-Myc inhibition-induced closed-loop regulatory circuit.Materials today. Bio · 2026Article
- Article
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation.European radiology · 2026Article
- Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma.Nature communications · 2026Article
- Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants.Biomolecules · 2026Review
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Immunotherapy for early-stage cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Review
- Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?Journal for immunotherapy of cancer · 2026Review
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- Priorities for local immunotherapy research and drug development.Journal for immunotherapy of cancer · 2026Review
- A Perplexing Plexopathy After Pembrolizumab Therapy in Early-Stage Triple-Negative Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Letter to the editor: Toward more precise and translational assessment of RAMIE in esophageal cancer surgery.International journal of surgery (London, England) · 2026Article
- Rapid assessment of immune effector cell-mediated cytotoxicity using mRNA lipid nanoparticles.Frontiers in immunology · 2026Article
- Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.Frontiers in immunology · 2026Review
- Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells.Frontiers in immunology · 2026Article
- Immune checkpoint inhibition inFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant immunotherapy is rapidly changing the treatment landscape for many tumor types. The superiority of neoadjuvant compared to adjuvant immunotherapy has now been established in both preclinical studies and clinical trials. Neoadjuvant immunotherapy, either as monotherapy or in combination with other immune checkpoint inhibitors or other agents, has become a standard of care for several cancer types, while many new indications are expected. Future research should focus on determining the benefit of treatment combinations versus monotherapy and the contribution of adjuvant after neoadjuvant (or perioperative) treatment versus neoadjuvant treatment alone as well as on identifying predictive biomarkers of response.
Indexed as
Identifiers
40555863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.